MLAB - Mesa Laboratories, Inc.
Mesa Laboratories, Inc. (NASDAQ: MLAB - Get Free Report) shares reached a new 52-week high on Monday. The company traded as high as $139.60 and last traded at $140.8960, with a volume of 78444 shares traded. The stock had previously closed at $132.55. Analyst Ratings Changes A number of equities analysts have issued reports on the
On September 02, 2026, Mesa Laboratories Inc (MLAB) shares rose 4.1% to $130.65, reflecting a significant increase within a volatile 52-week range of $58.83 to
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) and ImmunoPrecise Antibodies (OTCMKTS:IPATF - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations. Earnings and Valuation This table compares Mesa Laboratories
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced it will release financial results for its first fiscal quarter (“1Q27”) ended June 30, 2026 following market close on Monday, August 10, 2026. The Company will also hold its first earnings conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.
Mesa Laboratories fell after reporting its Q4 fiscal 2026 results. Sales and earnings came in below Wall Street's expected earnings, but the business did report strong growth for adjusted operating income.
LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q26”) and fiscal year (“FY26”) ended March 31, 2026 (amounts in thousands).
LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026.
LAKEWOOD, Colo. , April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0. 16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.
Mesa Laboratories, Inc. (NASDAQ: MLAB - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $79.16 and traded as high as $82.50. Mesa Laboratories shares last traded at $81.13, with a volume of 99,075 shares traded. Analyst
Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.
Principal Financial Group Inc. lessened its stake in Mesa Laboratories, Inc. (NASDAQ: MLAB) by 66.2% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,065 shares of the medical instruments supplier's stock after selling 19,713 shares during the quarter. Principal Financial Group
Diamond Hill Capital Management Inc. grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ: MLAB) by 218.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,381 shares of the medical instruments supplier's stock after purchasing an additional 84,582
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of $2.41 per share and revenue of $63.2330 million for the quarter. Individuals may visit the the company's upcoming Q3 2026 earning results page for
Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript